

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30TH JUNE, 2009

(Rs.in Lacs)

Sr. No.	Particulars	Quarter ended 30/06/2009	Corresponding Quarter ended 30/06/2008	SIX Months Ended 30/06/2009	Corresponding SIX Months Ended 30/06/2008	For the Year Ended 31/12/2008
		Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income					
	a) Net Sales/Income from Operations	35,763.65	27,694.29	70,721.14	54,597.90	117,838.07
	b) Other Operating Income	116.20	350.43	279.35	568.85	1,003.26
	c) Total	35,879.85	28,044.72	71,000.49	55,166.75	118,841.33
2	Expenditure					
	a) (Increase)/decrease in stock in trade and work in progress	(3,989.32)	(339.01)	(8,512.64)	(2,037.08)	313.09
	b) Consumption of raw materials	19,842.25	10,015.42	38,401.84	20,802.60	42,153.95
	c) Employees Cost	993.16	860.87	1,965.40	1,703.23	3,522.48
	d) Depreciation	3,006.85	2,557.33	6,013.78	5,019.79	10,715.18
	e) Other expenditure	7,272.89	5,023.61	14,065.43	9,975.91	21,718.36
	f) Total	27,125.83	18,118.22	51,933.81	35,464.45	78,423.06
3	Profit from Operations before Other Income and Interest (1-2)	8,754.02	9,926.50	19,066.68	19,702.30	40,418.27
4	Other Income	0.00	0.00	0.00	0.00	0.00
5	Profit before Interest (3+4)	8,754.02	9,926.50	19,066.68	19,702.30	40,418.27
6	Interest	3,113.42	1,068.41	6,107.62	2,241.19	5,920.71
7	Profit (+) / Loss (-) from Ordinary Activities before tax (5-6)	5,640.60	8,858.09	12,959.06	17,461.11	34,497.56
8	Tax expense					
	a) Current	910.00	1,000.00	1,760.00	1,950.00	3,750.00
	b) Deferred	400.00	1,850.00	1,800.00	3,700.00	7,550.00
	c) Fringe Benefit	0.00	12.00	12.50	23.00	47.50
	d) Total	1,310.00	2,862.00	3,572.50	5,673.00	11,347.50
9	Net Profit (+)/Loss (-) from Ordinary Activities after tax (7-8)	4,330.60	5,996.09	9,386.56	11,788.11	23,150.06
10	Extraordinary Items	283.16	283.16	566.32	566.32	1,132.64
11	Net Profit (+)/Loss (-) for the period (9-10)	4,047.44	5,712.93	8,820.24	11,221.79	22,017.42
12	Prior year adjustment	0.00	0.00	0.00	0.00	99.29
13	Profit available for appropriation	4,047.44	5,712.93	8,820.24	11,221.79	21,918.13
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,492.32	2,340.22	2,492.32	2,340.22	2,437.98
15	Reserves excluding Revaluation Reserves as per balance sheet.					170,359.64
16	Earnings Per Share (EPS)					
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.74	2.56	3.77	5.04	9.50
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.	1.62	2.44	3.54	4.80	9.03
17	Public Shareholding					
	- Number of shares	132,702,208	117,491,690	132,702,208	117,491,690	127,267,548
	- Percentage of shareholding	53.24%	50.21%	53.24%	50.21%	52.20%
18	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	Number of shares	32,488,136		32,488,136		32,488,136
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	36.49%		36.49%		36.49%
	Percentage of shares (as a % of the total share capital of the Company)	13.04%		13.04%		13.33%
	b) Non-encumbered					
	Number of shares	56,546,558		56,546,558		56,546,558
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	63.51%		63.51%		63.51%
	Percentage of shares (as a % of the total share capital of the Company)	22.69%		22.69%		23.19%

STERLING BIOTECH LIMITED
REGD. OFFICE: 43, ATLANTA, NARIMAN POINT, MUMBAI - 400 021

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE SECOND QUARTER ENDED 30TH JUNE, 2009

Notes:

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 31st July, 2009.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 30th June, 2009
- 4 During the Quarter the Company has issued 410,605 equity shares of Re.1/- each pursuant to conversion of FCCBs.
- 5 The number of investor complaints for the quarter ended on 30th June, 2009 were : Opening - 1, Received - 8, Disposed off - 9, and Balance - NIL.
- 6 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of
STERLING BIOTECH LIMITED

Place : Mumbai
Date : 31st July, 2009.

Chetan J. Sandesara
Joint Managing Director